Jeffrey Enevoldsen
Optometrist · Lees Summit, MONPI 1558617993
Payments from drug & device makers
Across 92 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$255
- Sun Pharmaceutical Industries Inc.$244
- Alcon$226
- Bausch & Lomb Americas Inc.$214
- Oyster Point Pharma, Inc.$194
- Johnson & Johnson Vision Care, Inc.$167
- plus $591 from 11 others
What the payments were for
- Consulting fees$201%
- Food & beverage$1,87199%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 14 | $255 |
| Sun Pharmaceutical Industries Inc. | 13 | $244 |
| Alcon | 14 | $226 |
| Bausch & Lomb Americas Inc. | 11 | $214 |
| Oyster Point Pharma, Inc. | 9 | $194 |
| Johnson & Johnson Vision Care, Inc. | 10 | $167 |
| Glaukos Corporation | 2 | $140 |
| Novartis | 5 | $105 |
| Menicon America Inc | 3 | $66 |
| The Cameron-ehlen Group, Inc. | 1 | $60 |
| Kala Pharmaceuticals, Inc. | 2 | $48 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $43 |
| Dompe US, Inc. | 1 | $33 |
| Tarsus Pharmaceuticals, Inc. | 1 | $33 |
| Mallinckrodt Hospital Products Inc. | 2 | $31 |
| AbbVie | 1 | $19 |
| Alcon Research LLC | 1 | $14 |
How this compares
$1,891 in reported general payments places this provider in the 70th percentile of 1,030 optometrist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 11 | $13,698 |
| Latanoprost | 58 | $723 |
| Prednisolone Acetate | 12 | $342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $19 | $13,69811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,030 optometrist providers in Missouri.
Other optometrist in Lees Summit
- Mark HerriottLees Summit$14K
- Robert WeixeldorferLees Summit$14K
- Anthony VerachtertKansas City$959K
- Joseph CastellanoSaint Louis$369K
- Richard WilsonRaytown$355K
- Lawrence ReedRaytown$317K
- Andrew BiondoKirkwood$300K
- Nicholas CastellanoSaint Louis$171K
- Geoffrey PowellKansas City$154K
- John McGrealSaint Louis$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.